With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

Britain's life sciences sector plan receives a mixed reception from the pharmaceutical industry. While the strategy aims to boost R&D, industry leaders criticize the lack of resolution on drug pricing ...

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and ...

Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which welcomed proposals to boost R&D but warned it would fail to keep firms competitive ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

Allergy care market grows with rising allergy cases, biologic innovations, and demand for personalized, accessible treatment solutions wor ...

Prior to this, he spent nine years in senior finance roles at GSK, latterly managing a global budget in the Consumer Health R&D team. Simon is a member of ... and manufacturing strategy. He was most ...

As the HR function rapidly evolves to keep pace with a changing world of work, India’s most distinguished people leaders and ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

GSK's business development team have been working overtime of late, with three R&D deals announced in the last few days across Alzheimer's disease and cancer. The Alzheimer's agreement – with ...